Secondary Hyperparathyroidism
Conditions
Keywords
Mineral bone disease(MBD), Chronic kidney disease(CKD), secondary hyperparathyroidism(SHPT)
Brief summary
To examine efficacy and safety after 12-week administration of ASP7991 in secondary hyperparathyroidism patients undergoing hemodialysis
Detailed description
This study is a multicenter, double-blind, randomized, Cinacalcet hydrochloride-controlled, parallel-group, dose-ascending study. Subjects judged to be eligible will be registered and randomized into either ASP7991 group (receiving ASP7991 and cinacalcet-placebo) or Cinacalcet group (receiving cinacalcet and ASP7991-placebo), and will receive 12-week (84 days) administration of study drug from first dialysis day in a week (treatment period), in a double-blind manner. The dose of the study drugs will be increased every 3 weeks in dose-ascending manner. Follow-up assessment will be performed before starting first dialysis in a week, 1 week (7 days) after the completion of the treatment period.
Interventions
Sponsors
Astellas Pharma Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
* Patients who are on stable chronic maintenance dialysis who are receiving hemodialysis therapy 3 times/week since before 12-week (84 days) administration and are also scheduled to undergo the regimen of 3 times/week hemodialysis during the study period * Patients with secondary hyperparathyroidism * Patients whose serum iPTH concentration is \>240 pg/mL and corrected serum Ca is ≥ 9.0 mg/dL * Patients who have had no changes in the following items ≥4-week (28 days). * Dosage and regimen, including new administration, of active vitamin D, calcitonin preparation, phosphate binder, and medication with phosphate absorption (including foods) * Ca concentration of the dialysate, membrane area of the dialyzer, and dialysis time of each week
Exclusion criteria
* Patients who underwent parathyroid intervention, such as parathyroidectomy (PTx) or percutaneous ethanol injection therapy (PEIT), within 24 weeks (168 days) prior to the administration * Patients who have primary hyperparathyroidism * Patients who received bisphosphonate, estrogen preparation, parathyroid hormone within 4 weeks (28 days) * Patients with uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg and diastolic blood pressure ≥ 120 mmHg are observed at \>2/3 of all confirmable measurements * Patients who are complicated by severe heart disorder \[congestive cardiac failure (NYHA classification III or higher), or wide range of old myocardial infarction\], or having a history of hospitalization for cerebro-vascular disease or heart disorder within 12 weeks (84 days) before administration of the study drug * Patients with hepatic function abnormal (ALT or AST is \>2× ULN, or total bilirubin (T-bil) is \> 1.5 × ULN.) * Patients with a history of malignant tumor or the patient's condition is complicated by malignant tumor. (However, enrollment is acceptable if the tumor has not relapsed for 5 years or longer.) * Patients with a history of serious drug allergy including anaphylactic shock * Patients with a history of drug allergy to Cinacalcet hydrochloride * Female patients who are potentially child-bearing or lactating, or patients who do not comply with the instructed contraceptive measures * Patients who were or are currently involved in trials for other investigational drugs or medical devices, or clinical trial for post-marketing study drugs within 12 weeks (84 days) before the study * Patients who have received ASP7991 in the past * Patients who were judged ineligible to participate in the study by the investigator / subinvestigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum iPTH concentration | Before and at 8, 15, 22, 24, 29, 36, 43, 45, 50, 57, 64, 66, 71, 78, 85 and 92 days after start of the treatment | iPTH: intact parathyroid hormone |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Corrected serum Ca, Phosphate(P) concentration | Before and at 3, 8, 15, 22, 24, 29, 36, 43, 45, 50, 57, 64, 66, 71, 78, 85 and 92 days after start of the treatment | Ca x P will be calculated |
| serum vitamin D concentration | Before and at 22, 43, 64, 85 and 92 days after start of the treatment | — |
| Safety assessed by the incidence of adverse events, vital signs, laboratory tests and 12-lead ECGs | For 12 weeks after start of treatment | — |
| Serum concentration of bone metabolism markers | Before and at 22, 43, 64, 85 and 92 days after start of the treatment | Bone metabolism markers will be BAP (Bone specific alkaline phosphatase) and TRACP5b (Tartrate-resistant acid phosphatase-5b) |
| Serum FGF23 concentration | Before and at 22, 43, 64, 85 and 92 days after start of the treatment | — |
| serum wPTH concentration | Before and at 22, 43, 64, 85 and 92 days after start of the treatment | wPTH: whole parathyroid hormone |
Countries
Japan
Outcome results
None listed